newsfilter
← Latest News
GlobeNewswire·

MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia

Results presented by the LiBBY study team at the Alzheimer’s Association International Conference ("AAIC") demonstrated statistically significant improvements in agitation symptoms compared with placebo.The